1. Home
  2. MLYS vs SWBI Comparison

MLYS vs SWBI Comparison

Compare MLYS & SWBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • SWBI
  • Stock Information
  • Founded
  • MLYS 2019
  • SWBI 1852
  • Country
  • MLYS United States
  • SWBI United States
  • Employees
  • MLYS N/A
  • SWBI N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • SWBI Ordnance And Accessories
  • Sector
  • MLYS Health Care
  • SWBI Industrials
  • Exchange
  • MLYS Nasdaq
  • SWBI Nasdaq
  • Market Cap
  • MLYS 590.3M
  • SWBI 587.1M
  • IPO Year
  • MLYS 2023
  • SWBI N/A
  • Fundamental
  • Price
  • MLYS $13.99
  • SWBI $13.29
  • Analyst Decision
  • MLYS Strong Buy
  • SWBI Strong Buy
  • Analyst Count
  • MLYS 2
  • SWBI 2
  • Target Price
  • MLYS $30.00
  • SWBI $18.00
  • AVG Volume (30 Days)
  • MLYS 152.5K
  • SWBI 482.7K
  • Earning Date
  • MLYS 11-12-2024
  • SWBI 12-05-2024
  • Dividend Yield
  • MLYS N/A
  • SWBI 3.95%
  • EPS Growth
  • MLYS N/A
  • SWBI N/A
  • EPS
  • MLYS N/A
  • SWBI 0.75
  • Revenue
  • MLYS N/A
  • SWBI $509,924,000.00
  • Revenue This Year
  • MLYS N/A
  • SWBI $6.69
  • Revenue Next Year
  • MLYS N/A
  • SWBI $6.31
  • P/E Ratio
  • MLYS N/A
  • SWBI $17.64
  • Revenue Growth
  • MLYS N/A
  • SWBI 0.16
  • 52 Week Low
  • MLYS $5.85
  • SWBI $11.96
  • 52 Week High
  • MLYS $16.91
  • SWBI $18.05
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 57.43
  • SWBI 52.23
  • Support Level
  • MLYS $13.33
  • SWBI $12.25
  • Resistance Level
  • MLYS $15.25
  • SWBI $14.10
  • Average True Range (ATR)
  • MLYS 0.63
  • SWBI 0.45
  • MACD
  • MLYS -0.01
  • SWBI 0.06
  • Stochastic Oscillator
  • MLYS 59.25
  • SWBI 63.61

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

About SWBI Smith & Wesson Brands Inc.

Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.

Share on Social Networks: